financetom
Business
financetom
/
Business
/
AeroVironment Top-line Growth, Margin, 2025 Outlook to Be Focus of Upcoming Results, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AeroVironment Top-line Growth, Margin, 2025 Outlook to Be Focus of Upcoming Results, RBC Says
Jun 25, 2024 10:02 AM

12:32 PM EDT, 06/25/2024 (MT Newswires) -- AeroVironment's ( AVAV ) focus in the fiscal Q4 results will be top-line growth, margin expansion, and initial fiscal 2025 guidance, RBC Capital Markets said in a note Monday.

The company is scheduled to release fiscal results June 26.

Analysts, including Ken Herbert, said the company has made "significant progress" in gaining more of the market share in key US defense programs with its Switchblade and small unmanned aircraft systems, or SUAS. However, shifting more towards loitering munitions might affect profit margins and could lower future investor expectations.

The analysts said that they expect discussions during AeroVironment's ( AVAV ) investor day, planned for day after the Q4 results, to primarily focus on changes in the competitive environment for loitering munitions, along with updates on contract awards and the medium-term Total Addressable Market outlook, including financial details.

Following recent contract announcements, the analysts expect management to discuss additional opportunities to boost revenue for fiscal 2025-26. Investors will likely be interested in details about the planned capital expenditure, expected around $30 million to $40 million, to increase production capacity.

"With the incremental contract announcements and the company's opportunity set across their loitering munition and SUAS portfolios, we believe sentiment will remain favorable," the analysts said.

RBC adjusted its price target on AeroVironment ( AVAV ) to $200 from $185, while keeping its outperform rating.

Price: 190.28, Change: -0.21, Percent Change: -0.11

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sunrun Unusual Options Activity For June 03
Sunrun Unusual Options Activity For June 03
Jun 3, 2024
Financial giants have made a conspicuous bullish move on Sunrun ( RUN ). Our analysis of options history for Sunrun ( RUN ) revealed 19 unusual trades. Delving into the details, we found 68% of traders were bullish, while 21% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $725,700, and 13...
National HealthCare Agrees to Acquire White Oak Senior Living Portfolio
National HealthCare Agrees to Acquire White Oak Senior Living Portfolio
Jun 3, 2024
03:09 PM EDT, 06/03/2024 (MT Newswires) -- National HealthCare ( NHC ) said Monday it entered an agreement to acquire White Oak Senior Living portfolio in North Carolina and South Carolina. Friday's agreement includes 15 skilled nursing facilities, adding 1,928 skilled nursing beds, 48 assisted living units, and more than 300 independent living units to National HealthCare's ( NHC )...
Silvaco Analysts Recommend The Stock As Unique Small-Cap Opportunity In Semiconductor Design
Silvaco Analysts Recommend The Stock As Unique Small-Cap Opportunity In Semiconductor Design
Jun 3, 2024
Rosenblatt analyst Blair Abernethy initiated coverage on Silvaco Group Inc ( SVCO ) with a Buy rating and a price target of $26. According to Abernethy, Silvaco ( SVCO ), which conducted its initial public offering (IPO) in early May, will continue to benefit from the secular tailwinds driving the electronic design automation (EDA) software market. It is well-positioned to leverage...
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Jun 3, 2024
On Monday, Structure Therapeutics Inc. ( GPCR ) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks. Cantor Fitzgerald maintains its bullish views on Structure Therapeutics ( GPCR ) and keeps the Overweight rating with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved